Patient Site Healthcare Professional Site
VIVITROL (naltrexone for extended-release injectable suspension) VIVITROL: A Treatment Option For The Daily Struggle Against Alcohol Dependence. One dose all month long.
Patient Site
Patient Information
Send to a Friend
Homepage About Vivitrol Links Contact Us SEARCH
About VIVITROL About VIVITROL
My Path to Recovery
What is VIVITROL?


How VIVITROL works


What to expect from treatment


The role of counseling


Is VIVITROL right for you?


Common Questions


Featured in this section:
Taking VIVITROL
How VIVITROL helps
Side effects
Locate a Physician

What is VIVITROL?

VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to treatment initiation. Patients should not be actively drinking at the time of initial VIVITROL administration. VIVITROL should be part of a comprehensive management program that includes psychosocial support.

VIVITROL is a long-acting form of naltrexone and has been shown to be generally well tolerated and effective for the treatment of alcohol dependence as part of a comprehensive management program.

Unlike other medications that need to be taken every day, VIVITROL is taken just once a month.

Many people find it extremely hard to take a medicine for alcoholism every single day. There can be several reasons for this. They might not remember to take it, they might not like taking it because of the side effects, or they just might not be ready to take medicine every day to help them manage their drinking.1

Unlike other medications, that need to be taken every day, VIVITROL is taken just once a month.
Important Safety Information
Naltrexone has the capacity to cause hepatocellular injury when given in excessive doses. Naltrexone is contraindicated in acute hepatitis or liver failure, and its use in patients with active liver disease must be carefully considered in light of its hepatotoxic effects. The margin of separation between the apparently safe dose of naltrexone and the dose causing hepatic injury appears to be only five-fold or less. VIVITROL does not appear to be a hepatotoxin at the recommended doses. Patients should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms of acute hepatitis. Use of VIVITROL should be discontinued in the event of symptoms and/or signs of acute hepatitis.
VIVITROL is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL.

Patients should not be actively drinking at the time of initial VIVITROL administration.

Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support.